Rakovina Therapeutics

Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response (DDR) technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancertherapeutics from Health Canada, the United States Food and Drug administration and similar international regulatory agencies.